


Synopsis of the original article
'Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: Combined post hoc analysis of the SUSTAIN and PIONEER trials'

Husain M, et al. *Cardiovasc Diabetol.* 2020;19:156

Synopsis created and reviewed by Novo Nordisk

Introduction



However, there is little evidence for an effect of semaglutide on MACE in patients not at high risk of CV events


This post hoc analysis examined the CV effects of semaglutide in subjects across a continuum of baseline CV risk

CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MACE, major adverse cardiovascular events; MI, myocardial infarction; s.c., subcutaneous

Synopsis of the original article 'Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: Combined post hoc analysis of the SUSTAIN and PIONEER trials' Husain M, et al. *Cardiovasc Diabetol.* 2020;19:156

© 2021 Novo Nordisk A/S; Further reproduction and distribution is permitted

Semaglutide reduced the risk of MACE across the entire continuum of CV risk



*The CV-risk prediction model performed satisfactorily when applied to the pooled semaglutide data (AUC 0.77)

AUC, area under the curve; CV, cardiovascular; MACE, major adverse cardiovascular events

Synopsis of the original article 'Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: Combined post hoc analysis of the SUSTAIN and PIONEER trials' Husain M, et al. *Cardiovasc Diabetol.* 2020;19:156

© 2021 Novo Nordisk A/S; Further reproduction and distribution is permitted

Conclusions



Semaglutide reduced the risk of MACE vs comparators across the entire continuum of CV risk in a broad T2D population

Relative risk reduction tended to be largest with low CV risk score; the largest absolute risk reduction was for intermediate to high CV risk score.



The results were similar for:

Relative risk reduction of the individual MACE components

Comparison between semaglutide and placebo only